Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001012975-26-000043·FENNEC PHARMACEUTICALS INC.
Schedule 13G ownership disclosure
Fennec Pharmaceuticals Inc
Common Shares, no par value · CUSIP: 31447P100
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Southpoint Master Fund, LP
Shares: 2,744,741 · Class: 8.0%
- Southpoint Capital Advisors LP
Shares: 2,744,741 · Class: 8.0%
- Southpoint Capital Advisors LLC
Shares: 2,744,741 · Class: 8.0%
- Southpoint GP, LP
Shares: 2,744,741 · Class: 8.0%
- Southpoint GP, LLC
Shares: 2,744,741 · Class: 8.0%
- John S. Clark II
Shares: 2,744,741 · Class: 8.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001012975-26-000043
- Form type
- SCHEDULE 13G/A
- Filer
- FENNEC PHARMACEUTICALS INC.
- CIK
- CIK 1211583
- Filed
- Jan 14, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership